Outputs from the ISARIC4C consortium
This page is intended to provide updates for participants on the work that has been done with their samples and data. We will keep this page updated with research results, reports and plans.
During its first 3 months, the ISARIC4C consortium expanded from the initial 34 co-investigators to more than 150 active contributors, and provides a data and sampling infrastructure for follow-up of COVID cases in the P-HOSP consortium.
As well as these outputs, see the dynamic report of age, sex, and 28 day status of patients admitted with COVID.
Risk prediction: the 4C Mortality Score
BMJ 9 Mar 2020 The ISARIC 4C Mortality Score DOI: 10.1136/bmj.m3339 Using data from 57, 824 hos...
T cell activation
Nature Immunology (4th September 2020) Immune cells target many different parts of the virus ...
Characterisation of hospitalised cases of COVID-19
BMJ: 2020; 369 Quantifying the problem Within weeks of being funded, we produced the largest st...
Impact on children
BMJ 2020;370:m3249 Clinical characterisation of Covid-19 in children We have comprehensively ch...
Symptom clusters
MedRxiv August 16th 2020. Because of the large scale of the ISARIC-4C study, we were able to d...
Ethnicity
SSRN July 2020 Impact of ethnicity We have carefully studied the effect of ethnicity on outcome...
Genetics
MedRxiv September 2020; Nature online December 2020 Genetic mechanisms of severe Covid-19 In co...
Testing the tests
MedRxiv May 2020 We proposed and established a Diagnostic Evaluation Platform at the University ...
ICECAP autopsy study
MedRxiv June 2020 Supporting autopsy work ISARIC 4C resources and consortium partners supported...
Remdesivir Statistical Analysis Plan
The Remdesivir Statistical Analysis Plan was approved on 16 December 2020.
Setting Serology Standards
Setting the standard ISARIC 4C defined the international reference standard for SARS-CoV-2 serol...
Transmission
Medrxiv June 2020 Transmission dynamics of COVID-19 We have explored the mechanisms of viral tr...
